Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
Mult Scler Relat Disord
; 4(4): 380-2, 2015 Jul.
Article
em En
| MEDLINE
| ID: mdl-26195060
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Esclerose Múltipla Recidivante-Remitente
/
Natalizumab
/
Fatores Imunológicos
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article